Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

30 years of research has highlighted the crucial role of oestrogen in the disease profile of women with psychotic disorders. However, we have not translated this knowledge into tailored treatment strategies. I will present the work conducted during my PhD, which focused on the impact of sex and sex hormones, particularly oestrogen, o the disease trajectory and treatment of psychotic disorders. In the first part, I will explore the interplay between sex, oestrogen, and current treatment strategies for psychosis, emphasising the links between hyperprolactinaemia and clinical outcomes. as well as the influence of sex on the effectiveness and tolerability of antipsychotics. In the second part, I will discuss how we might harness the beneficial effects of oestrogen to optimise treatment strategies, drawing on evidence from clinical trials and birth cohort studies. Lastly, I will provide a brief overview of our current efforts to better understand the impact of sex hormones on the disease course of schizophrenia-spectrum disorders, with the aim of advancing care. 

 

This seminar is hosted in person and online, to join via Zoom, please use the details below: